Prognosis
Pfizer Boosts EU Vaccine Supply as J&J Review Accelerates
- Drugmaker accelerates deliveries from later in the year
- EU regulator to issue recommendation on J&J next week
This article is for subscribers only.
Pfizer Inc. and BioNTech SE will raise Covid-19 vaccine deliveries to the European Union by 25% this quarter, helping the bloc overcome delays to the shot from Johnson & Johnson as the drug regulator speeds up its safety review.
The U.S. drugmaker and its partner will bring forward 50 million deliveries scheduled for the fourth quarter, adding to the 200 million doses already planned. The company provided about 66 million in the first three months of the year.